Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Signs on PPO Stratose

NEW YORK (GenomeWeb News) – MDxHealth today announced an agreement with preferred provider organization Stratose that gives its 12.4 million members access to the ConfirmMDx prostate cancer test.

Formerly operating as Coalition America, NPPN, OPPN, PlanCare America, 4MOST Health, Qualident and KeyClaims, Stratose has 850,000 direct and affiliate medical, dental, and workers' compensation provider contracts, MDxHealth said.

Jan Groen, CEO of MDxHealth, said that Stratose's network supplements more than 90 different third-party insurance payers. "With the addition of Stratose to our existing payer agreements, more than 80 million covered lives now have access to ConfirmMDx for prostate cancer," he said in a statement.

Today's announcement is the third deal MDxHealth has inked with a payor. In late July it said it signed agreements with healthcare cost management firm MultiPlan and PPO Three Rivers Provider Network to provide access to ConfirmMDx.

In late August, the Belgian firm said that revenues through the first half of 2013 had doubled year over year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.